Sanofi and Exscientia have entered a research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology, leveraging Exscientia’s end-to-end AI-driven platform utilizing actual patient samples.   The companies have been working together since 2016 and in 2019, Sanofi licensed Exscientia’s novel bispecific small molecule candidate capable of targeting two distinct targets in inflammation and immunology.   “We look forward to deepening ou...